WaveMan
WaveMan · Company
NGVT · Ingevity Corp
> Search tickers & screens ⌘K
LIVE
← All companies

NGVT Ingevity (NGVT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Chemicals & allied products · CIK 0001653477
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
153
13F, latest reported quarter

What the filings say about NGVT

Insiders, 180 days
-$1.8M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$1.8M
2 notices

Ingevity insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Ingevity Corp insiders sold a net $1.8M of stock across 20 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Li David H
President & CEO
SELL
2026-08-18 SEC
92
$6.9K
-2.1%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 17, 2026.
  • The trade is 0.1% of the 120,544 shares held after it.
  • 1 other insider sold within 30 days.
  • 153 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Li David H sold about $6.9K of NGVT on Aug 18, 2026; 1 other insider sold within 30 days and 153 funds added in the latest 13F quarter.
Li David H
President & CEO
SELL
2026-08-18 SECtraded 2026-08-17
5,000
$379.1K
-2.1%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Aug 14, 2026.
  • The trade is 4.1% of the 120,636 shares held after it.
  • 1 other insider sold within 30 days.
  • 153 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Li David H sold about $379.1K of NGVT on Aug 17, 2026; 1 other insider sold within 30 days and 153 funds added in the latest 13F quarter.
Li David H
President & CEO
SELL
2026-08-18 SECtraded 2026-08-14
5,000
$378.6K
-2.1%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 13, 2026.
  • The trade is 4.0% of the 125,636 shares held after it.
  • 1 other insider sold within 30 days.
  • 153 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Li David H sold about $378.6K of NGVT on Aug 14, 2026; 1 other insider sold within 30 days and 153 funds added in the latest 13F quarter.
Li David H
President & CEO
SELL
2026-08-14 SECtraded 2026-08-13
5,000
$378.6K
-8.1%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 12, 2026.
  • The trade is 3.8% of the 130,636 shares held after it.
  • 1 other insider sold within 30 days.
  • 153 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Li David H sold about $378.6K of NGVT on Aug 13, 2026; 1 other insider sold within 30 days and 153 funds added in the latest 13F quarter.
Li David H
President & CEO
SELL
2026-08-14 SECtraded 2026-08-12
5,000
$383.1K
-8.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 3.7% of the 135,636 shares held after it.
  • 1 other insider sold within 30 days.
  • 153 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Li David H sold about $383.1K of NGVT on Aug 12, 2026, the largest insider sale at the company since 2023; 1 other insider sold within 30 days and 153 funds added in the latest 13F quarter.
20 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 15 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.8M over 180 days
-$1.7M over 90 days
below 69% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
153 funds bought in last quarter
more than 83% of Pharma & Biotech
Revenue
-2.7% year over year
below 60% of Pharma & Biotech
Margin
-14.3% net margin
more than 61% of Pharma & Biotech
Buybacks
$86.8M repurchased, FY to 2026-06-30
more than 66% of Pharma & Biotech
Short interest
4.3% of the float short (float per yahoo 2026-10-26) · 4.8 days to cover · settled 2026-09-30
below 53% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch NGVT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+24.7%12M
-17%+2%+21%+39%2025-102025-122026-022026-042026-062026-082026-10 2026-08-12 · Li David H sold $383.1K2026-08-17 · Li David H sold $379.1K2026-08-13 · Li David H sold $378.6K2026-08-14 · Li David H sold $378.6K2026-08-03 · Fisher Ryan C. sold $103.0K2026-08-03 · Fisher Ryan C. sold $96.7K2026-05-28 · DYER TERRANCE M sold $18.2K2026-05-28 · DYER TERRANCE M sold $13.7K2026-08-18 · Li David H sold $6.9K2026-05-28 · DYER TERRANCE M sold $2.1K2026-08-12 · DAVID H LI filed to sell $1.6M2026-08-03 · RYAN C FISHER filed to sell $199.7K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns NGVT: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
5,364,204 sh
$400.5M
VANGUARD PORTFOLIO MANAGEMENT LLC
2,376,803 sh
$177.5M
VANGUARD CAPITAL MANAGEMENT LLC
1,571,127 sh
$117.3M
STATE STREET CORP
1,497,321 sh
$111.8M
AMERICAN CENTURY COMPANIES INC
1,270,958 sh
$94.9M

Congress trades in NGVT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

NGVT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
DAVID H LI
Filed 2026-08-12
$1.6M
RYAN C FISHER
Filed 2026-08-03
$199.7K

NGVT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco S&P SmallCap Materials ETF
$673.1K position · as of 2026-05-31
3.2%
Select Chemicals Portfolio
$13.6M position · as of 2026-05-31
3.1%
SBH SMALL CAP VALUE FUND
$13.0M position · as of 2026-06-30
2.9%
Brown Advisory Small-Cap Fundamental Value Fund
$34.3M position · as of 2026-06-30
2.8%
Royce Small-Cap Total Return Fund
$25.5M position · as of 2026-06-30
2.7%
iMGP Small Company Fund
$1.4M position · as of 2026-06-30
2.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.8M sold by insiders over 180 days, 153 funds added last quarter, $1.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

NGVT financials

Revenue growth
-2.7%
XBRL, annual
Net margin
-14.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Free cash flow, TTM
$154.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
25.59x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.18x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
+64.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+3.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
+31.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
46.43x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$3.5B
market value at close 2026-10-23 on 2026-07-24 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
+6.5%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$1.2B$1.4B$1.7B$1.7B
Gross profit$461.5M$464.8M$445.0M$570.1M
Operating income$418.7M$425.9M$423.2M$452.6M
Net income-$167.1M-$430.3M-$5.4M$211.6M
EPS (diluted)-4.61-11.85-0.155.50
Operating cash flow$331.2M$128.6M$205.1M$313.4M
Cash$78.1M$68.0M$95.9M$76.7M
Long-term debt$1.2B$1.3B$1.4B$1.5B
Buybacks$56.3M$0$92.1M$145.2M
SEC XBRL, fiscal years, as known on 2026-10-27

NGVT Stock Sonar score 6/7 axes

Find similar shapesCompare

NGVT ranks highest on profitability (92nd percentile) and institutional and government (72nd), and lowest on insider conviction (15th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
92
Inputs
  • Return on equity+64.4% · 95 pct, sector of 545
  • Return on assets+3.2% · 84 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed+31.7% · 97 pct, sector of 576
Financial health
40
Inputs
  • Debt to equity25.59x · 0 pct, sector of 352
  • Cash flow to debt0.18x · 80 pct, sector of 371
Growth
40
Inputs
  • Revenue growth, YoY-2.7% · 40 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
15
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.8M · 29 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
72
Inputs
  • Funds adding, latest quarter153 · 83 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$440K · 62 pct, sector of 133
Risk and compliance
47
Inputs
  • Short interest, % of float+4.3% · 62 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+14.2% · 32 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

NGVT filings, in plain words

Are Ingevity insiders buying or selling NGVT?

In the 180 days to 2026-10-27, Ingevity insiders were net sellers, a net $1.8M across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of NGVT?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $1.8M of stock; the latest, by DAVID H LI, was filed 2026-08-12.

Read the full summary

In the 180 days to 2026-10-27, Ingevity insiders were net sellers of NGVT, a net $1.8M across purchases and sales reported on Form 4 by 3 sellers. None of the 10 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $1.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies